Predicting response to azacitidine in MDS



Micrograph showing MDS
Research published in Cell Reports helps explain why some patients with myelodysplastic syndrome (MDS) do not respond to treatment with azacitidine. The study showed that patients who were resistant to the drug had relatively quiescent hematopoietic progenitor cells (HPCs). A smaller proportion of their HPCs were undergoing active cell-cycle progression when... [Read Article]

Vaccine granted orphan designation for MDS



Micrograph showing MDS
The US Food and Drug Administration (FDA) has granted orphan drug designation to DSP-7888, an investigational cancer peptide vaccine, for the treatment of myelodysplastic syndromes (MDS). DSP-7888 contains peptides to induce Wilms' tumor gene 1 (WT1)-specific cytotoxic T lymphocytes and helper T cells, which attack WT1-expressing cancerous cells found in... [Read Article]

Luspatercept appears safe, effective in β-thalassemia



Blood for transfusion
Photo from UAB Hospital
Results of a phase 2 study have shown that luspatercept can produce sustained increases in hemoglobin and reductions in transfusion burden in adults with β-thalassemia. Some patients are still receiving the drug and experiencing clinical benefits beyond 24 months. Luspatercept has been well-tolerated in these patients,... [Read Article]

FDA clears use of reagents to detect hematopoietic neoplasia



Blood samples
Photo by Graham Colm
The US Food and Drug Administration (FDA) has allowed marketing of the ClearLLab Reagent Panel, a combination of conjugated antibody cocktails designed to aid the detection of hematopoietic neoplasia. This includes chronic and acute leukemias, non-Hodgkin lymphoma, myeloma, myelodysplastic syndromes, and myeloproliferative neoplasms. The ClearLLab reagents are... [Read Article]

T-cell product improves outcomes of haplo-HSCT



HSCT preparation
Photo by Chad McNeeley
Preliminary results of a phase 1/2 study suggest the T-cell product BPX-501 lowers the risks associated with haploidentical hematopoietic stem cell transplant (haplo-HSCT). In this ongoing study, researchers are testing BPX-501 in pediatric patients undergoing haplo-HSCT to treat a range of hematologic disorders. Patients treated thus far... [Read Article]